>>> READY TO SHIP PRODUCT
axoCells™ human iPSC-derived retinal pigment epithelial cells (unaffected), male donor, aged 30, ≥2 million cells, PCi-RPE
axoCells™ human iPSC-derived retinal pigment epithelial cells (unaffected), male donor, aged 30, ≥2 million cells, PCi-RPE for toxicology testing, dry AMD research and drug discovery. Cells made from iPSCs which were generated from a 30-year-old Caucasian male donor’s PBMCs.
• Derived from human iPSCs
• Assay ready in 4 weeks
• Express the typical markers including MITF, ZO-1 and PMEL17
• Exhibit functional response in phagocytosis assays
• Can be used to fuel advanced in vitro models for toxicology testing, dry AMD research and drug discovery
Specifications
Number of cells ≥2 million
Donor Male, 30 years old
Genetics Healthy control
Description
Human iPSC-Derived Retinal Pigment Epithelial cells (≥2 million cells) for toxicology testing, dry AMD research and drug discovery. RPE cells made from iPSCs generated from a 30 year old Caucasian male donor’s PBMCs.
Key highlights include:
• Derived from human iPSCs
• Assay ready in 4 weeks
• Express the typical markers including MITF, ZO-1 and PMEL17
• Exhibit functional response in phagocytosis assays
• Can be used to fuel advanced in vitro models for toxicology testing, dry AMD research and drug discovery
These cells are frequently used in in vitro toxicology models and dry AMD models for research and drug discovery.
Top Resources
Additional Information
Phenotypic relevance: Morphology
Human iPSC-derived RPE cells demonstrate typical cobblestone morphology and pigmentation on microscopy.
Phenotypic relevance: ICC
RPE cells express key markers MITF, ZO-1 and PMEL17 on ICC.
Phenotypic relevance: flow cytometry
Flow cytometry demonstrating >95% PMEL 17 expression (blue) against isotype control (black).
Functional relevance: phagocytosis
The phagocytotic potential of iPSC-derived RPE cells was assessed using a pH-Rhodo bioparticle assay (Thermo Fisher), demonstrating phagocytotic activity in 57.2% of the RPE cells, which is within the range described in the literature.
Recapitulating AMD pathophysiology in advanced in vitro models
We utilize chronic N-retinylidene-N-retinylethanolamine (A2E) treatment combined with blue light irradiation to induce apoptosis, oxidative stress and inflammation. This helps to better reproduce pathological AMD conditions to produce more human-relevant AMD models.
A2E treatment combined with blue light can reproduce AMD conditions. A: Images demonstrating enhanced cell death with combination treatment (A2E and blue light) versus vehicle control and blue light. B: Increasing A2E concentrations produce a significant increase in cell death. This assay was used to guide the most appropriate concentration of A2E for chronic treatment. Ns: P > 0.05, **** P ≤ 0.0001.
Model validation: demonstrating dry AMD phenotype
We have performed extensive characterization to validate our dry AMD model against key hallmarks of the disease, including pro-inflammatory cytokine release (Fig 3A.), AMD-associated drusen protein expression (Fig 3B.), oxidative stress (Fig 3C.) and complement immunostaining (Fig 3D).
Demonstration of dry AMD phenotype across several assays. A: ELISA assay demonstrating significantly enhanced release of pro-inflammatory cytokines IL-6 and IL-8 by RPE cells with A2E treatment versus vehicle control. B: qPCR demonstrating significantly increased expression of APOE and APOJ (encoding drusen transport proteins implicated in dry AMD) by RPE cells with A2E treatment, versus vehicle control. C: CellROXTM assay demonstrating oxidative stress produced by addition of A2E to RPE cells, versus vehicle control. D: Immunostaining assay demonstrating increased RPE cell expression of complement protein C3 with A2E treatment versus vehicle control. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001
Applications
Our RPE cells have been specifically developed for use in advanced in vitro ophthalmology models for toxicology testing, research and drug discovery.
We have a community of biopharma and research institutes that use our RPE cells to build powerful in vitro models for toxicology screening and to model ophthalmic disorders (including dry AMD) for drug discovery.
Quality
Guided by over a decade of expertise, we ensure confidence in the quality of our iPSC-derived cells with rigorous QC. All cells come with a full Certificate of Analysis to ensure ethical and biological conformity for your peace of mind.
Licenses & Consent
Axol has obtained all relevant licenses for reprogramming donor samples into iPSCs and differentiating these into RPE cells for commercial use.
Patient samples used to create these RPE cells have been ethically sourced and consented for research and commercial use. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Publications
TBC
Media and Reagents
- RPE culture medium
- Supplement A